Abstract: The present invention provides an ionizable polymer comprising a constitutional unit according to formula (I). wherein R1 and R2 are as defined in the specification. The ionizable polymer of the invention finds use in the intracellular delivery of polynucleotides in vitro and in vivo. The present invention also provides compositions comprising the ionizable polymer of the invention and a polynucleotide. The compositions disclosed herein find utility as medicaments, in particular as medicaments for the prevention or treatment of an infectious disease, a cancer, or a protein-deficiency disease.

Abstract: A hydrostatic radial piston unit of the cam-lobe type of construction including a shaft defining a rotational axis of the hydrostatic radial piston unit. The shaft extends with a front end region from a non-rotary, stationary rear casing to a front casing. Within the front casing a cylinder block is housed and fixed in a torque-proof connection to the front end region of the shaft. In the cylinder block radially reciprocating working pistons are disposed in radially oriented cylinder bores to and from which cylinder bores hydraulic fluid can be conducted by means of a distributor. The distributor is arranged rotationally fixed with respect to the front casing and rotationally free relative to the shaft. A circumferential cam-lobe surface with which the working pistons can interact, is formed integrally with the front casing on its radial inner side.

Abstract: A hydrostatic radial piston unit of the cam-lobe type of construction including a non-rotary, stationary casing. The stationary casing includes a through hole defining a rotational axis of the hydrostatic radial piston unit. A rotary casing is mounted rotary to the non-rotary, stationary casing in an axial overlapping area. A park brake mechanism includes at least two brake discs arranged adjoined in the overlapping area. An end cover closes the non-rotary casing on a rear end side of the hydrostatic radial piston unit facing away from the rotary casing. The end cover pre-tensions a disc spring against a disc-shaped brake piston both located in the rear end portion of the stationary casing to generate an axially oriented spring force.

Abstract: The present invention provides a compound targeting SSTR2, a preparation method therefor and a use thereof, and relates to the fields of nuclear medicine and molecular imaging. The compound targeting SSTR2 has a structure shown in a formula (I) below, and a compound targeting SSTR2 and capable of being labeled with a radionuclide has a structure shown in a formula (II) below. The present invention further provides a radionuclide labeled compound targeting SSTR2 that is obtained by labeling the compound shown in the formula (II) with a radionuclide. The present invention further provides methods for preparing the compounds shown in the formula (I) and the formula (II) and a use of the compounds in preparation of drugs for diagnosis and/or treatment of diseases characterized by over-expression of SSTR2.

Abstract: The present invention provides an RGD dimer compound, a preparation method therefor and use thereof, and relates to the fields of nuclear medicine and molecular imaging. The RGD dimer compound has a structure shown in Formula (I) or Formula (I-1). The present invention further provides a radionuclide labeled compound with the RGD dimer compound shown in Formula (I-1) as a ligand, a pharmaceutical composition containing or composed of the RGD dimer compound, and a kit containing or composed of the RGD dimer compound or the pharmaceutical composition. The present invention further provides use of the RGD dimer compound or the pharmaceutical composition in diagnosis or treatment of diseases characterized by over-expression of an integrin ?v?3. The RGD dimer compound and the radionuclide labeled compound of the present invention have higher tumor uptake and a longer retention time and are expected to be used in diagnosis or treatment of diseases characterized by over-expression of the integrin ?v?3.

Abstract: The present invention relates to a dual-targeting compound capable of targeting fibroblast activation protein (FAP) and integrin ?v?. The targeting compound of the present invention and a radionuclide marker thereof can synergistically target an FAP target and an integrin ?v?3 target in tumors, such that the number and utilization efficiency of effective receptors in tumors can be improved. The present invention further provides a radionuclide marker based on the targeting compound, a preparation method therefor and use thereof in diagnosis or treatment of diseases characterized by overexpression of fibroblast activation protein (FAP) and/or integrin ?v?3.

Abstract: A hydrostatic radial piston unit of the cam-lobe type of construction having a non-rotary, stationary shaft defining a rotational axis of the hydrostatic radial piston unit. A non-rotary, stationary casing houses the shaft in a torque proof connection. A rotary casing is provided which is rotary around the rotational axis. A pair of roller bearings supports the rotary casing in a rotatable manner against the stationary casing, wherein the pair of roller bearings is arranged in an axial overlapping area in which the stationary casing and the rotary casing overlap.

Abstract: Disclosed is a system comprising an artificial enzyme, a probiotic bacteria and a linker to conjugate the artificial enzyme and probiotic bacteria. Further disclosed are compositions comprising the said system and the uses thereof.

Abstract: A compound of Formula I or a pharmaceutically acceptable ester, amide, solvate, or salt thereof, or a salt of such an ester or amide or a solvate of such an ester amide or salt: wherein the definitions of R1-R13 and L1-L4 are provided in the disclosure, and wherein R14 is a group capable of binding to prostate-specific membrane antigen (PSMA).

Abstract: A hydrostatic radial piston unit of the cam-lobe type of construction including a non-rotary, stationary casing. The stationary casing includes a through hole defining a rotational axis of the hydrostatic radial piston unit. A rotary casing is mounted rotary to the non-rotary, stationary casing in an axial overlapping area. A park brake mechanism includes at least two brake discs arranged adjoined in the overlapping area. An end cover closes the non-rotary casing on a rear end side of the hydrostatic radial piston unit facing away from the rotary casing. The end cover pre-tensions a disc spring against a disc-shaped brake piston both located in the rear end portion of the stationary casing to generate an axially oriented spring force.

Abstract: A hydrostatic radial piston unit of the cam-lobe type of construction having a non-rotary, stationary shaft defining a rotational axis of the hydrostatic radial piston unit. A non-rotary, stationary casing houses the shaft in a torque proof connection. A rotary casing is provided which is rotary around the rotational axis. A pair of roller bearings supports the rotary casing in a rotatable manner against the stationary casing, wherein the pair of roller bearings is arranged in an axial overlapping area in which the stationary casing and the rotary casing overlap.

Abstract: The present disclosure provides a truncated Evans Blue modified fibroblast activation protein inhibitor compound. The compound is formed by connecting truncated Evans Blue, a fibroblast activation protein inhibitor and a nuclide chelating group by means of connecting groups L1, L2, L3, L4 and X. The compound has the following structure shown in Formula (I), where R1 is a fibroblast activation protein inhibitor; L1 is lysine, glutamic acid, or a derivative structure thereof; L2 is —(CH2)n—, n is an integer from 0 to 30, and each —CH2— may be individually substituted or unsubstituted with —O—, —NH—, —(CO)—, —NH(CO)—, or —(CO)—NH—; L3 is —(CH2)m—, m is an integer from 0 to 30, and each —CH2— may be individually substituted or unsubstituted with —O— or —(CO)—; L4 is —(CH2)p—, p is an integer from 0 to 30, and each —CH2— may be individually substituted or unsubstituted with —O—, —NH—, —(CO)—, —NH(CO)—, or —(CO)—NH—; X is selected from N, C, O, S, or and R2 is a nuclide chelating group.

Abstract: The present disclosure relates to the fields of nuclear medicine and molecular imaging, and specifically relates to a dual-targeting compound and a preparation method and application thereof. The dual-targeting compound has the following structure shown in Formula (I). The present disclosure also provides a dual-targeting compound capable of being labeled with a radionuclide, and the compound has the following structure shown in Formula (I-1) or Formula (1-2). The dual-targeting compound of the present disclosure has high affinity for an FAP target and an integrin ?v?3 target, can realize synergistic targeting of the FAP target and the integrin ?v?3 target in tumors, and has high uptake in tumors and long retention time in tumors.

Abstract: The present disclosure provides a truncated Evans Blue modified fibroblast activation protein inhibitor compound. The compound is formed by connecting truncated Evans Blue, a fibroblast activation protein inhibitor and a nuclide chelating group by means of connecting groups L1, L2, L3, L4 and X. The compound has the following structure shown in Formula (I), where R1 is a fibroblast activation protein inhibitor; L1 is lysine, glutamic acid, or a derivative structure thereof; L2 is —(CH2)n—, n is an integer from 0 to 30, and each —CH2— may be individually substituted or unsubstituted with —O—, —NH—, —(CO)—, —NH(CO)—, or —(CO)—NH—; L3 is —(CH2)m—, m is an integer from 0 to 30, and each —CH2— may be individually substituted or unsubstituted with —O— or —(CO)—; L4 is —(CH2)p—, p is an integer from 0 to 30, and each —CH2— may be individually substituted or unsubstituted with —O—, —NH—, —(CO)—, —NH(CO)—, or —(CO)—NH—; X is selected from N, C, O, S, or and R2 is a nuclide chelating group.

Abstract: The present disclosure relates to the fields of nuclear medicine and molecular imaging, and specifically relates to a dual-targeting compound and a preparation method and application thereof. The dual-targeting compound has the following structure shown in Formula (I). The present disclosure also provides a dual-targeting compound capable of being labeled with a radionuclide, and the compound has the following structure shown in Formula (I-1) or Formula (I-2). The dual-targeting compound of the present disclosure has high affinity for an FAP target and an integrin ?v?3 target, can realize synergistic targeting of the FAP target and the integrin ?v?3 target in tumors, and has high uptake in tumors and long retention time in tumors.

Abstract: The present disclosure provides a compound targeting prostate specific membrane antigen (PSMA), wherein the compound has the following structure shown in Formula (I); R1 is a compound structure targeting prostate specific membrane antigen; L1 is -(X)n-(CH2)m-(Y)q-, X and Y are independently selected from lysine, glutamic acid or a derivative structure containing lysine and glutamic acid, n is an integer from 0 to 12, m is an integer from 0 to 60, q is an integer from 0 to 12, and each CH2 may be individually substituted with —O—, —NH(CO)—, or —(CO)—NH—; L2 is -(CH2)p-, p is an integer from 0 to 30, and each CH2 may be individually substituted with —O—, —NH(CO)—, or —(CO)—NH—; and R2 is a nuclide chelating group. The present disclosure also provides a radiolabeled complex based on the structure of the compound.

Abstract: The present disclosure provides a compound targeting prostate specific membrane antigen (PSMA), wherein the compound has the following structure shown in Formula (I); R1 is a compound structure targeting prostate specific membrane antigen; L1 is —(X)n—(CH2)m—(Y)q—, X and Y are independently selected from lysine, glutamic acid or a derivative structure containing lysine and glutamic acid, n is an integer from 0 to 12, m is an integer from 0 to 60, q is an integer from 0 to 12, and each CH2 may be individually substituted with —O—, —NH(CO)—, or —(CO)—NH—; L2 is —(CH2)p—, p is an integer from 0 to 30, and each CH2 may be individually substituted with —O—, —NH(CO)—, or —(CO)—NH—; and R2 is a nuclide chelating group. The present disclosure also provides a radiolabeled complex based on the structure of the compound.